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ABSTRACT
OBJECTIVE: The objective of this systematic EBM review is to determine whether or not the
administration of depot medroxyprogesterone acetate injections every three months are effective
in decreasing pain associated with endometriosis in premenopausal women.
STUDY DESIGN: A review of two randomized controlled trials and one randomized
comparative trial comparing pain improvement from depot medroxyprogesterone acetate
(DMPA) injections at different time intervals and/or in comparison to other hormonal birth
control methods in premenopausal patients suffering from endometriosis.
DATA SOURCES: Randomized controlled trials and a randomized comparative trial were
found using PubMed and Ovid MEDLINE databases.
OUTCOME MEASURED: Outcomes were measured for reduction of pain by a verbal rating
scale and/or a 10-cm or a 100-mm visual analog scale.
RESULTS: Wong et al found that the pain score was significantly reduced all through the study
period as long as the therapy of 150mg DMPA intramuscular injection every three months was
continued (in all patients but one). Both Cheewadhanaraks et al and Walch et al showed a
decreased in pain scores with DMPA in comparison to the control, but neither article calculated
statistics comparing these scores to the baseline, therefore results are inconclusive whether or not
pain associated with endometriosis is decreased with administration of DMPA injections every
three months in premenopausal women.
CONCLUSION: Based on the articles reviewed, one of the articles showed evidence that 150mg
injections of DMPA administered every three months is an effective means of decreasing
endometriosis-associated pain in premenopausal women. The other two articles had inconclusive
results, therefore further research is warranted.
KEYWORD: Depot Medroxyprogesterone Acetate, DMPA, Endometriosis

Kern, “DMPA Injections in Endometriosis Pain”, 1
INTRODUCTION
Endometriosis is a chronic and recurrent condition where endometrial tissues grow in
areas of the body outside the uterus leading to pelvic pain, dysmenorrhea, and infertility.1
Normally each month the cells lining the uterus increase in thickness following the release of
hormones from the ovaries. These cells then shed from the endometrial lining during a woman’s
menstrual period. If instead the endometrial cells implant outside the uterus, endometriosis
occurs resulting in tissue implanting in various organs in the pelvic region. This misplaced tissue
is not shed monthly but it stays in place and grows during menstruation thereby frequently
causing cyclic bleeding, scarring, and dysmenorrhea.2
It is estimated approximately 6-20% of reproductive-age women1 are affected by
endometriosis thereby afflicting approximately 167 million women worldwide and 8.5 million in
North America4. The prevalence of endometriosis is assumed to be around 10% of women of
reproductive age3, 5 making it a prominent concern for healthcare providers. The average cost of
endometriosis is $12,500/year per woman ($8,200 lost in work productivity; $4,000 for direct
health care costs). Costs were higher with increasing severity of disease and the presence of
dysmenorrhea6, although they may vary according to socioeconomic status and individual
insurance policies regarding coverage of treatment options. In the United States alone,
endometriosis-associated costs are estimated to be $22 billion annually.4 Yearly healthcare visits
vary, however a woman with endometriosis sees 4-5 doctors prior to being correctly diagnosed.6
This estrogen-dependent condition is most commonly associated with dysmenorrhea but
it may also cause dyspareunia, infertility, fatigue, dysuria, pain during bowel movements, and
other gastrointestinal symptoms.1, 6 Endometriosis is usually diagnosed between 25-35 years of
age although the condition is thought to have developed around the beginning of a girl’s
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menstrual cycle. Women with a family history of the condition, who never had children,
developed their period at a young age, have frequent or long periods, or have a closed hymen are
more likely to develop endometriosis.2 The cause of endometriosis is unknown; however, the
retrograde menstruation theory proposes that during a woman’s cycle part of the menstrual tissue
backs up through the oviducts then implants and grows in the abdomen. There are theories that
this tissue is sent from the uterus to other body parts via the lymph or blood system.6
Additionally, it has been proposed that stem cells, genetics, dysfunctional immune responses,
and environmental sources all may contribute in some way to this multi-factorial condition.4
Pain medication, hormonal therapy, surgery, traditional Chinese medicine, nutritional
changes, homeopathy, allergy control, and immune therapy are all treatment options for
endometriosis, as there is no cure.6 Treatment depends on age, severity of symptoms and disease,
and whether a woman wants to become pregnant in the future.2 Mild symptoms may be managed
with exercise, relaxation techniques, and non-steroidal anti-inflammatory drugs (NSAIDs). In
order to halt the disease progression, hormone medications have been shown to reduce most
symptoms.2 The gold standard for women who have no improvement with other treatment
methods and are still experiencing severe pain is pelvic laparascopic excision surgery to remove
all endometrial implants and adhesions.2, 4 Hysterectomy, including ovary removal of ovaries, is
a last resort for persistent symptoms in women who do not wish to have future children.2
For many women with moderate and severe endometriosis, they still run a high risk of
symptoms associated with the disease after conservative surgery. Studies have shown that
hormonal therapies are equally effective in the control of endometriosis-associated pain, but their
side effects and costs differ.7 Because hormonal therapy is less invasive and more affordable

Kern, “DMPA Injections in Endometriosis Pain”, 3
than surgery and often offers less systemic side effects than antiestrogrens1, many hormonal
methods have been utilized to determine their effect on endometriosis-associated dysmenorrhea.
Depot medroxyprogesterone acetate (DMPA), a birth control drug, is a 17-hydroxy
derivate progestogen with moderate androgenic activity that is administered intramuscularly in
attempt to decrease endometriosis-associated pain. This paper evaluates three randomized
controlled/comparative trials comparing the effectiveness of DMPA injections every three
months in decreasing endometriosis-associated pain in premenopausal women. This systemic
review compares DMPA injections given every three months to DMPA administered every
month for six months followed by every three months, a levonorgestrel-releasing intrauterine
system, and a single-rod etonogestrel-containing contraceptive implant.1, 3, 7 All regimens are
primarily hormonal birth control methods.
OBJECTIVE
The objective of this systematic review is to determine whether or not the administration
of depot medroxyprogesterone acetate injections every three months are effective in decreasing
pain associated with endometriosis in premenopausal women.
METHODS
The population selected for this study included premenopausal women between the ages
of eighteen and fifty years old who were experiencing endometriosis-associated pain. The
intervention applied in the systemic review was 150mg DMPA intramuscular injection given
every three months. The comparisons were to 150mg DMPA intramuscular injection
administered every month for six months followed by every three months, a levonorgestrelreleasing intrauterine system (Mirena), a single-rod etonogestrel-containing contraceptive
implant (Implanon).1, 3, 7 The outcome measured is reduction of pain and was evaluated by a
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verbal rating scale and a 10-cm or a 100-mm visual analog scale according to specific criteria.
The types of studies included three randomized controlled/comparative trials.
A detailed literature search was conducted using PubMed and Ovid MEDLINE. The
searches were conducted from December 2011 until December 2012. The keywords searched for
were “Medroxyprogesterone Acetate”, “Depoprovera”, and “Endometriosis”. Each article was
published originally in English in peer reviewed journals. The articles were researched and
selected based on relevance and patient oriented outcomes that matter to them (POEMS).
Inclusion criteria are composed of studies that were randomized controlled/comparative trials
that included POEMS and administered a DMPA dosage of 150mg. Exclusion criteria include
articles with patients under the age of eighteen and over the age of fifty years old and those that
were published prior to 2009. Statistics reported or used include p-value, baseline median, 95%
confidence interval (CI), student t-test, Experimental Event Rate (EER), Controlled Event Rate
(CER), Relative Benefit Increase (RBI), Absolute Benefit Increase (ABI), and Numbers Needed
to Treat (NNT). Table 1 includes the demographics of the studies analyzed in this review.
Table 1: Demographics & Characteristics of Included Studies
Study

Type

Age
(years)
18-46
years

Inclusion Criteria

Exclusion Criteria

RCT

#
Participants
112

Cheewa
dhanara
ks et al
(2009)

Premenopausal
women from 18 to 46
years of age who had
endometriosisassociated pain for at
least 6 months and
did not wish to
conceive in the next 2
years or more

RCT

41

22-44
years

Women with
symptomatic Stage IIV endometriosis
proven by
laparoscopy or
laparotomy prior to
inclusion;
dysmenorrhea and

Medical therapies for
endometriosis other
than NSAIDs within
last 6 months;
contraindications to
DMPA; request for
extirpative surgery;
ovarian endometioma
>2cm; other pelvic
pathology; GI, urologic,
or orthopedic diseases
Desire to conceive; +
hCG test; suspicious
Pap; uterine or adnexal
anomalies
endometriosis; large
adenomas; any
malignancy; performed
hysterectomy, C/I to

Walch
et al
(2009)

W/
D
42

11

Interventions
150 mg
DMPA
injections
every month
for 6 months
then every 3
months for
15 months or
every 3
months for
15 months
Implanon
(subdermal
implantation
) or 150 mg
DMPA
injections
every 3
months
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Wong et
al
(2010)

RCT

30

≥
30
years

menstrual
irregularities
associated with
endometriosis and no
desire to conceive
within the next 12
months; premenopausal; grade
severity of
dysmenorrhea,
nonmenstrual pelvic
pain, dyspareunia on
a 100-mm visual
analog scale with a
mean score >50 over
a period of 14 days,
including one
menstrual bleeding
Premenopausal
patients age ≥30,
history of surgery
performed in past 5
years for moderate or
severe endometriosis;
no evidence of lesion
recurrence or
osteoporosis from a
DEXA scan on
lumbar spine/hip; no
desire for pregnancy
within 3 years;
patient agreed to
hormonal therapy

progestins; use of an
oral contraceptive pill
within 1 month; l use of
injectable hormonal
treatments during the
last 3 months before
study

None given

10

Mirena
(LNG-IUS)
or 150 mg
MPA every
3 months

OUTCOMES MEASURED
All outcomes measured were based on relevance to Patient Oriented Evidence that
Matters, or POEMS. Although all three of the studies had multiple POEMS, this systematic
review focuses specifically on the outcome of pain associated with endometriosis. One of the
articles measured pain on a verbal rating scale from 0-3 (0 – no pain, 1 – mild pain not requiring
intervention, 2 – moderate pain requiring analgesics, 3 – intolerable pain).7 The second article
measured pain using a 100-mm visual analog scale where a score higher than fifty over a
fourteen day period was necessary for inclusion.1 The third article utilized both a verbal rating
scale from 0-3 (0 – no pain, 1 – no absence from work but decrease efficiency, 2 – absence from
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work <1 day per cycle, 3 – absence from work ≥ 1 day per cycle) and a 10-cm visual analog
scale from 0-10 (0 – absence of pain, 10 – unbearable pain) to measure pain.3
RESULTS
All three articles presented in this systematic review are randomized
controlled/comparative trials that compare 150mg of DMPA intramuscular injections every three
months to other birth control methods or DMPA administered during different time intervals to
determine its efficacy at decreasing endometriosis-associated pain in premenopausal women.1, 3, 7
Wong et al conducted a randomized controlled trial comparing levonorgestrel-releasing
intrauterine system (LNG-IUS, or Mirena) to DMPA as long-term maintenance therapy for
patients with moderate and severe endometriosis. The study began with thirty premenopausal
patients >30 years of age with history of conservative surgery performed within five years for
moderate to severe endometriosis, no evidence of lesion recurrence or osteoporosis from a
DEXA scan on the lumbar spine or hip, no desire for pregnancy within three years, and the
patient agreed to receive hormonal therapy. There were no exclusion criteria. Fifteen of the
women were randomized into the LNG-IUS group and fifteen into the DMPA group.7
The women in the LNG-IUS group had the product inserted into the uterus where it
released levonorgesterol at a rate of 20 ug/24 hrs for up to five years at a virtually constant rate.
The 150mg DMPA intramuscular injections were administered every three months for three
years. Follow up in the first year was every three months, followed by every six months in the
second and third years. Zero patients were lost to follow-up although ten patients discontinued
the interaction due to adverse side effects – two from the LNG-IUS group and eight from the
DMPA group. As a result, the LNG-IUS had a better compliance rate.7
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After initiation of treatment, there was a decrease in the pain scores three months later
with both LNG-IUS (p<0.02) and DMPA (p<0.002), as well as a decrease throughout the rest of
the study for all patients except one on DMPA. As shown in Table 2, there was a change in the
mean from the baseline for LNG-IUS of 1.5 and DMPA of 1.2. At thirty-six months, LNG-IUS
was found to be significantly lower in pain scores versus DMPA although no statistics were
reported. Overall, the pain score throughout the study between the two variables was statistically
significant with a p-value of <0.025. Both the control and intervention were found to be effective
in decreasing pain associated with endometriosis when compared to the baseline pain level.7
Table 2: Summary of Pain Scores Over 36 Months
# of
Pain Score
Patients
Change in Mean
From Baseline
15
1.5 (1.6-0.1)
LNG-IUS
1.2 (1.9-0.7)
Depot MPA 15
*Statistical comparison was by Student t test

Pain Score p-value p-value at 36mo
from Baseline-3mo between LNG-IUS
and Depot MPA
<0.02
<0.025
<0.002
<0.025

Walch et al conducted a randomized controlled trial comparing the therapeutic efficacies
of Implanon, a single-rod etonogestrel-containing contraceptive implant administered
intradermally to prevent ovulation for at least three years, and 150mg DMPA intramuscular
injections every three months in relieving pain associated with endometriosis in premenopausal
women. The study began with forty-one premenopausal patients between 22-44 years of age with
symptomatic endometriosis who had no desire to conceive in the next twelve months and had a
mean VAS score >50 over fourteen days including one menstrual bleeding. Patients were
excluded with a desire to conceive, a positive hCG test, a suspicious Pap smear, uterine or
adnexal anomalies, large adenomas, any malignancy, performed hysterectomy, contraindications
to progestins, oral contraceptive pill usage within one month, or injectable hormonal treatments
during the last three months before study entry. Eleven women withdrew due to adverse side
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effects, the desire to conceive, or a dwelling change – four from the Implanon group and seven
from the DMPA group, but this dropout rate was not considered statistically significant.1
During the one year study, there was a marked reduction in pain intensity after
administration of both Implanon and DMPA. This study focused its primary outcome measure in
regards to pain reduction at the six month mark when compare to baseline.1 Since the
dichotomous data was given, the control event rate (CER), experimental event rate (EER),
absolute benefit increase (ABI), relative benefit increase (RBI), and number needed to treat
(NNT) were calculated. The CER is the percentage of patients receiving Implanon whereas the
EER is those receiving DMPA. The ABI is the increase of a good event as a result of DMPA.
The RBI is the proportional increase in the rate of good outcomes between the Implanon and
DMPA groups. The number needed to treat determines the number of people needed to be
treated in order to prevent one patient from experiencing pain associated with endometriosis.
The mean decrease in VAS scores (quantifying pain intensity) after the first six months
was 68% with a 95% CI (53-83) for the Implanon group and 53% with a 95% CI (28-79) in the
DMPA group. The NNT value was -6 signifying that for every six patients treated with
Implanon, one less patient experienced pain associated with endometriosis compared to DMPA,
as shown in Table 3. The difference between these two groups was not shown to be statistically
significant with p=0.36, where significance was achieved when p<0.05. On month six, the VAS
score for the Implanon group was not statistically significant compared to the DMPA group with
p=0.69. There was no statistical difference in VAS scores between treatment groups when
analyzed (p=0.8). When comparing Implanon to DMPA, the difference in VAS scores was not
statistically significant. When compared to baseline, each regimen individually showed a marked
decrease in pain scores although analysis was not performed making the data inconclusive.1
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Table 3: Analysis of Pain Reduction at 6 Months in Relevance to RBI/ABI/NNT
Controlled Experimental p-value Relative
Absolute
Event
Event Rate
Benefit
Benefit
Rate
(EER)
Increase
Increase
(CER)
(RBI)
(ABI)
0.53
p=0.36
0.221
-0.15
Walch et al 0.68

Numbers
Needed to
Treat
(NNT)
-6

Cheewadhanaraks et al conducted a randomized comparative trial comparing 150 mg
DMPA intramuscular injections every month for six months then every three months for fifteen
months (regimen A) to injections every three months for fifteen months (regimen B) to
determine the optimal interval in the long-term treatment in pain associated with endometriosis.
Patients were seen for a follow-up visit every three months. The study was conducted with 112
premenopausal women 18-46 years of age who had endometriosis-associated pain for at least six
months and did not wish to conceive in the next two years or more. Exclusion criteria included
medications for endometriosis besides NSAIDs within last six months, contraindications to
DMPA, extirpative surgery request, ovarian endometioma >2cm (ruled out with transvaginal
ultrasound), other pelvic pathology, or known GI, urologic, and orthopedic diseases. In the two
months prior to the study, an initial laparoscopic diagnosis of endometriosis was performed and
staged according to the American Fertility Society classification system. Forty-two women
withdrew from the study, twenty-one from each regimen, due to persistent pain and adverse side
effects. This was not statistically significant since p=0.032 (p<0.05 was considered significant).3
Throughout the fifteen month study, there was a continual trend resulting in a decrease in
the pain scores between patients in both treatment regimens. At the six month time interval, there
was statistical significance achieved where there was a larger decrease in pain in regimen A in
comparison to regimen B as seen in Table 4. This table also shows the verbal rating scores
(VRS) during the six month time interval that was analyzed and found to be statistically
significant being the p-values were <0.05. Regardless of this outcome, there were no statistics
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conducted comparing pain scores from either regimen to baseline pain before beginning the
study. Therefore, although statistical significance was achieved at the sixth month time interval
when comparing regimen A to regimen B, in terms of answering the proposed question of this
review the results would have to be considered inconclusive due to lack of statistical analysis.3
Table 4: Verbal Rating Scale for Pain Intensity
0
1
35
8
Regimen A
26
12
Regimen B

2
0
6

3
0
1

p-value
0.012
0.009

DISCUSSION
All three studies showed a decrease in pain scores in comparison to the control in each
study, although Walch et al is the only study that showed statistical significance in reduction of
pain scores from DMPA when compared to baseline. DMPA is widely available with a
prescription from a healthcare practitioner. Most insurances that cover the birth control pill cover
the MDPA shot as well, although this can vary per individual. For those without insurance,
Planned Parenthood offers the shot at a discounted rate.8 DMPA is contraindicated in patients
with pregnancy or as a diagnostic test for pregnancy, thrombophlebitis, thromboembolic
disorders, cerebral vascular disease, breast malignancy, hypersensitivity to DMPA, liver disease,
or undiagnosed vaginal bleeding. Warnings and precautions of the drug include loss of bone
mineral density, thromboembolic disorders, cancer risks, ectopic pregnancy, anaphylaxis, liver
disturbances, convulsions, depression, bleeding irregularities, weight gain, carbohydrate
metabolism reduction, fluid retention, delayed fertility, and sexually transmitted diseases.9
The black box warning notes that DMPA causes increased osteoporotic effects the longer
it is administered, may remain after the injections cease, and may be irreversible. Pfizer, the
DMPA drug manufacturer, and the Food and Drug Administration advise that it should not be
used over a two year period unless no other options are feasible due to bone loss concerns. It is
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primarily used as a progestin hormone birth control method to prevent pregnancy. It causes a
change in menstrual periods of most women where they experience an increase or decrease in
flow, increased spotting, or amenorrhea.9 DMPA is also being used in nine states as a form of
chemical castration where it acts as a sexual suppressant in male sex offenders.10
All three of the articles reviewed had limitations to the studies which included small
sample sizes with significant drop out rates and no blinding. If the study sizes were larger, it is
possible that the results may have been different. In the future, it may be of interest to administer
DMPA injections to one group and placebo shots to another group, as long as the women
involved did not have concerns about becoming pregnant. This way both the patients and the
shot administrators would be unaware of which injection each woman was receiving making it a
double blinded study. It would also be helpful to perform statistical analysis on the decrease in
pain levels when compared to the baseline. This would show the effectiveness of each drug
individually, in addition to the comparison to other methods if warranted in the particular study.
CONCLUSION
According to the three articles selected for this systemic review, Walch et all showed that
the administration of depot medroxyprogesterone acetate injections every three months is
effective in decreasing pain associated with endometriosis in premenopausal women.1 Wong et
al and Cheewadhanaraks et al were found to be inconclusive. Although, all studies showed a
significant decrease in pain levels when compared to the control, the latter two studies did not
publish data comparing DMPA pain levels throughout the study to the initial baseline
measurements. Future study is warranted using a larger double blinded multicultural study that
looks at the administration of DMPA to a placebo and calculates statistical analysis on pain
reduction for the drug throughout the study in comparison to baseline.
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